Imphal News Flash

DelveInsight’s, “Crohn’s Disease Pipeline Insight 2026” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the Crohn’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Crohn’s Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Crohn’s Disease Treatment Landscape @ https://www.delveinsight.com/sample-request/crohns-disease-pipeline-insight

Key Takeaways from the Crohn’s Disease Pipeline Report

• On June 08, 2026- Janssen Research & Development LLC announced a phase 3 study is to assess how well JNJ-78934804 works (efficacy) and how safe it is (safety) as compared to guselkumab at Week 48 in participants with moderately to severely active Crohn’s disease (a long-term, progressive [worsens with time] and life-threatening disease of the intestine).
• On June 05, 2026- Xian-Janssen Pharmaceutical Ltd. announced a study is to evaluate how well guselkumab works in participants with Crohn’s disease (CD; a long-term condition causing severe inflammation of the intestinal tract) who no longer respond to treatment with ustekinumab.
• On June 05, 2026- Janssen-Cilag Ltd. initiated a phase 3 study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn’s disease and to assess the overall safety of guselkumab.
• On June 05, 2026- AbbVie conducted a phase 2a study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, trosunilimab, lutikizumab, and ABBV-8736. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 540 participants will be enrolled in the study at approximately 300 sites worldwide.
• On June 04, 2026- Eli Lilly and Company announced a phase 2 study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn’s disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
• On June 01, 2026- AstraZeneca initiated a phase II study designed to evaluate safety, tolerability, and mucosal repair with AZD7798 in participants with active ileal Crohn’s disease and an ileostomy. This study will include a screening period, an induction period, an open-label maintenance period, and a follow-up period. Approximately 30 participants will be randomized globally to receive either AZD7798 or placebo during 12-week participant- and investigator- blind induction period.
• DelveInsight’s Crohn’s Disease pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for Crohn’s Disease treatment.
• The leading Crohn’s Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
• Promising Crohn’s Disease Pipeline Therapies such as Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.

Gain in-depth knowledge of key Crohn’s Disease clinical trials, emerging drugs, and market opportunities @ Crohn’s Disease Clinical Trials Assessment

Crohn’s Disease Overview

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively. The inflammation observed in the digestive tract is followed by abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn’s disease in people can be both painful and weakening, sometimes leading to life-threatening complications. The inflammation caused in the intestine can be skipped in between the patches of diseased intestine. The signs and symptoms observed in patients suffering from Crohn’s disease tends to vary and can change over a period of time.

Crohn’s Disease Emerging Drugs Profile

• Guselkumab: Janssen

Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinical trial.

• RHB-104: RedHill Biopharma

RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III of clinical trial.

Crohn’s Disease Market Drivers

• Increasing Prevalence of Inflammatory Bowel Disease
• Development of New and Effective Therapies

Crohn’s Disease Market Barriers

• Limited awareness and education
• Failures and discontinuation of emerging therapies

The Crohn’s Disease Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Crohn’s Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Crohn’s Disease Treatment.
• Crohn’s Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Crohn’s Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Crohn’s Disease market

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Crohn’s Disease Unmet Needs

Crohn’s Disease Companies

Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Crohn’s Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

See the latest progress in drug development and clinical research @ Crohn’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Crohn’s Disease Pipeline Report

• Coverage- Global
• Crohn’s Disease Companies- Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, AbbVie, Mesoblast, Alfasigma, Tiziana Life Sciences, Abivax, Arena Pharmaceuticals, Cytocom, Priothera, SLA Pharma, HAV Vaccines Ltd, Enzo Biochem Inc., VHsquared Ltd., Stero Biotechs, Reistone Biopharma Company Limited, Qu Biologics, Provention Bio, Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceuticals, Soligenix, Immunic, Atlantic Healthcare, 4D Pharma, Landos Biopharma, Protagonist Therapeutics, Roche, Eisai, Bristol-Myers Squibb, Iltoo Pharma, Fast Forward Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Theravance Biopharma, TaiwanJ Pharmaceuticals, Active Biotech, Celularity, Cerecor, GlaxoSmithKline, Kang Stem Biotech, Alpha Cancer Technologies, Koutif Therapeutics, Winston Pharmaceuticals, Tract Therapeutics, Trio Medicines, Tetherex Pharmaceuticals, ChemoCentryx, Algernon Pharmaceuticals, Neuclone, Innovimmune Biotherapeutics, JHL Biotech, Intract Pharma Ltd, Innovative Pharmacological Research (IPHAR) Co Ltd, Innovation Pharmaceuticals, Exeliom Biosciences SAS, Finch Therapeutics, Akeso Biopharma, Draconis Pharma, MakScientific, Origo Biopharma, Navidea Biopharmaceuticals, Orchard Therapeutics, Xbrane, Thetis Pharmaceuticals, Temisis Therapeutics, Synedgen, Synlogic, PlantPraxis, Morphic Therapeutic, Metacrine, Curacle, Commence Bio Inc, Cloud Pharmaceuticals, Chong Kun Dang Pharmaceutical Corp, Avobis Bio LLC, Avexegen Therapeutics, Atlantic Bio Sci, Assembly Biosciences, Artelo Biosciences, Aibios Co Ltd, Aclaris Therapeutics, Athos Therapeutics, Denali Therapeutics, Educell doo and others.
• Crohn’s Disease Pipeline Therapies- Etrasimod, Infliximab, MEDI2070, Filgotinib, Risankizumab 600 mg IV, CT-P13, and others.
• Crohn’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Crohn’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Crohn’s Disease Pipeline Analysis Today! @ Crohn’s Disease Drugs and Companies

Table of Content

1. Introduction
2. Crohn’s Disease Executive Summary
3. Crohn’s Disease: Overview
4. Crohn’s Disease Pipeline Therapeutics
5. Crohn’s Disease Therapeutic Assessment
6. Crohn’s Disease– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Ozanimod: Bristol-Myers Squibb
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. CBP-307: Suzhou Connect Biopharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. IMU-856: Immunic
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Crohn’s Disease Key Companies
21. Crohn’s Disease Key Products
22. Crohn’s Disease- Unmet Needs
23. Crohn’s Disease- Market Drivers and Barriers
24. Crohn’s Disease- Future Perspectives and Conclusion
25. Crohn’s Disease Analyst Views
26. Crohn’s Disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/crohns-disease-pipeline-insight